Stay updated with breaking news from Nasdaq Regn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Coldstream Capital Management Inc. lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.7% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,171 shares of the biopharmaceutical company’s stock after selling 33 shares during the period. Coldstream […]
Coldstream Capital Management Inc. cut its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,171 shares of the biopharmaceutical company’s stock after selling 33 shares during the quarter. Coldstream […]
Forsta AP Fonden decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 1.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,300 shares of the biopharmaceutical company’s stock after selling 200 shares during […]
Cornerstone Wealth Group LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.0% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,269 shares of the biopharmaceutical company’s stock after acquiring an additional 102 shares […]
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price lifted by Cantor Fitzgerald from $800.00 to $850.00 in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Regeneron Pharmaceuticals’ FY2024 earnings at $34.70 EPS. REGN […]